UK: UK To Become More Attractive For Conducting Clinical And Field Trials

Last Updated: 11 April 2013
Article by Philip Bilney and Beatriz San Martín

Conducting clinical and field trials in the UK for innovative drugs can be a mine field due to the risk of infringing third party patents through the use of patented drugs in the trials or because the innovative drug infringes such patents.  The UK Government announced at the end of February that it supports amending the Patents Act 1977 to remove this uncertainty and make the UK a more attractive place to conduct clinical and field trials. 

The current UK legal position

The Patents Act 1977 contains a number of carve outs which exempt certain activities from patent infringement.  Section 60(5)(b) provides an "experimental use" exemption but it has been defined narrowly by the English Courts and it is unclear how far it extends.  Not all clinical trials are regarded as "experimental use", especially those which use a patented comparator.  Section 60(5)(i) exempts certain activities performed to obtain regulatory approval for generic drugs (the so-called "Bolar Exception"). However, this exemption does not extend to innovative drugs, unlike in other EU countries such as Germany.

The narrow scope of these exceptions and their impact on clinical and field trials have been an issue for stakeholders for some time as they run the risk of being sued for patent infringement when conducting research and tests required for the regulatory approval of innovative drugs.  In addition, Health Technology Assessments (HTAs) which, amongst other things, investigate how a new drug compares to alternatives currently on the market, are not exempt from patent infringement.

The Government response to the UK IPO consultation

To help address the situation, the UK IPO ran a formal consultation from 24 October to 19 December 2012 on proposals to amend the Patents Act 1977 to exempt activities relating to clinical or field trials for innovative drugs.  The Government's response to the consultation was published on 26 February 2013.  Twenty responses were received, of which all but one were in favour of change.  

There was general acceptance from respondents that the current legislation puts the UK at a competitive disadvantage compared to other EU countries with broader exceptions to patent infringement.  The proposed changes would bring certainty to the industry and align UK law with the majority of the EU countries.  

There were, however, differing views as to the scope of the new exemption and which of the three options put forward by the UK IPO should be followed.  One respondent expressed concern that the new exemption should not include marketing activities.  Another that it should not be applicable once the product was marketed.  Yet another that contributory infringement from, for example, CROs should be exempt.

Those respondents in favour of the inclusion of HTAs in the new exemption provided a number of supporting reasons including that HTAs are increasingly required in the UK and Europe, they are an onerous process requiring the use of third party products for comparative studies and it is desirable to generate HTA data from existing trial sites. 

Very little quantified evidence was provided by respondents as to potential costs savings to them or the losses that might be incurred by patentees or licensees through the proposed changes.  Several responses indicated that companies were being advised to do trial work in other jurisdictions and some did not consider running trials in the UK due to the risk of patent infringement.  Other respondents referenced the significant costs of FTO searches, validity challenges and defending infringement actions.  There was an acknowledgement by a number of respondents of the loss of licensing fees to patentees as a result of the proposed changes though the exact extent of the loss was unclear. 

In light of the comments received, the Government concluded that "section 60(5) of the Patents Act 1977 should be changed to include an exemption from infringement, for activities involved in preparing or running clinical or field trials involving innovative drugs for the purpose of gaining regulatory approval in any country.  The exemption should also cover activities involved in health technology assessment (HTA)".


Whilst the decision to include a new exemption in the Patents Act 1977 will, in principle, be welcomed in the industry, there is concern as to the exact scope of the exemption and the definition of terms such as: "HTAs", "innovative drugs" and "generic drugs".  The exercise will have been futile if clarity and certainty as to the boundaries of the new exemption cannot be provided.  The industry needs to know which acts will infringe and which will not.  Assuming this is achieved, the proposals should attract more research and trials in the UK which would be a positive outcome for the UK economy.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Beatriz San Martín
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.